Literature DB >> 12471626

Prevalence of human papillomavirus infection in women in Busan, South Korea.

Hai-Rim Shin1, Duk-Hee Lee, Rolando Herrero, Jennifer S Smith, Salvatore Vaccarella, Sook-Hee Hong, Kap-Yeol Jung, Hyun-Ho Kim, Un-Dong Park, Hyung-Su Cha, Soyoon Park, Antoine Touzé, Nubia Muñoz, Peter J F Snijders, Chris J L M Meijer, Pierre Coursaget, Silvia Franceschi.   

Abstract

To investigate the prevalence of and the risk factors for human papillomavirus (HPV) infection in South Korea, we interviewed and examined a randomly selected sample of 863 sexually active women (age range = 20-74 years, median 44) and 103 self-reported virgins from Busan. The presence of DNA of 34 different HPV types in cervical exfoliated cells was tested among sexually active women by means of a PCR-based assay. IgG antibodies against L1 virus-like particles (anti-VLPs) of HPV types 16, 18, 31, 33 and 58 were also evaluated by means of ELISA. The overall prevalence of HPV DNA was 10.4% (95% confidence interval, CI: 8.5-12.7%). The most often found HPV DNA types were HPV 70, HPV 16 and HPV 33; 19.8% (95% CI: 17.2-22.0) of sexually active women had antibodies against one or more HPV types. The most common anti-VLPs were against HPV 18, 31 and 16. Prevalences standardized by age on the basis of the world standard population were 13.0% for HPV DNA and 17.1% for anti-VLPs. The concordance between the 2 HPV markers at an individual level was modest, but the risk factors for detection of HPV DNA and anti-VLPs were similar: number of lifetime sexual partners (odds ratio, OR for >/= 4 vs. 1 = 3.5 and 5.4, respectively), seropositivity for herpes simplex virus-2 antibodies (OR = 2.6 and 2.5, respectively) and being single or divorced. HPV DNA, but not anti-VLPs, were elevated among women whose husbands were thought by their wives to have extra-marital affairs and those who had undergone vasectomy. Among 103 virgins, 4.9% had anti-VLPs (1/73 among those aged 24 years or less). Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12471626     DOI: 10.1002/ijc.10825

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  37 in total

Review 1.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

2.  The Prevalence of Human Papilloma Virus (HPV) in Women using Liquid Base Pap Smear in Rasht, Northern of Iran.

Authors:  Seyed Mohamad Mohseni Mehran; Mandana Mansour Ghanaei; Ali Mojtehadi
Journal:  J Clin Diagn Res       Date:  2015-07-01

3.  Gender and age-specific seroprevalence of human papillomavirus 16 and 18 in general population in Tehran, Iran.

Authors:  Arezoo Aghakhani; Setareh Mamishi; Shahram Sabeti; Farahnaz Bidari-Zerehpoosh; Mohammad Banifazl; Anahita Bavand; Amitis Ramezani
Journal:  Med Microbiol Immunol       Date:  2016-11-17       Impact factor: 3.402

4.  Human papillomavirus prevalence and genotype distribution among HIV-infected women in Korea.

Authors:  Eun Kyoung Park; Heerim Cho; Sun Hee Lee; Seung Geun Lee; Sang Yeup Lee; Ki Hyung Kim; Chang Hun Lee; Joo Seop Chung; Ihm Soo Kwak
Journal:  J Korean Med Sci       Date:  2013-12-26       Impact factor: 2.153

5.  Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic.

Authors:  Petroula Stamataki; Athanasia Papazafiropoulou; Ioannis Elefsiniotis; Margarita Giannakopoulou; Hero Brokalaki; Eleni Apostolopoulou; Pavlos Sarafis; George Saroglou
Journal:  BMC Infect Dis       Date:  2010-02-15       Impact factor: 3.090

6.  Determinants of seropositivity among HPV-16/18 DNA positive young women.

Authors:  Carolina Porras; Christina Bennett; Mahboobeh Safaeian; Sarah Coseo; Ana Cecilia Rodríguez; Paula González; Martha Hutchinson; Silvia Jiménez; Mark E Sherman; Sholom Wacholder; Diane Solomon; Leen-Jan van Doorn; Catherine Bougelet; Wim Quint; Mark Schiffman; Rolando Herrero; Allan Hildesheim
Journal:  BMC Infect Dis       Date:  2010-08-11       Impact factor: 3.090

7.  Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies.

Authors:  Troy J Kemp; Allan Hildesheim; Roni T Falk; John T Schiller; Douglas R Lowy; Ana Cecilia Rodriguez; Ligia A Pinto
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

8.  Differences in the risk of cervical cancer and human papillomavirus infection by education level.

Authors:  S Franceschi; M Plummer; G Clifford; S de Sanjose; X Bosch; R Herrero; N Muñoz; S Vaccarella
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

9.  Human papillomavirus infection in Beijing, People's Republic of China: a population-based study.

Authors:  R Zhao; W Y Zhang; M H Wu; S W Zhang; J Pan; L Zhu; Y P Zhang; H Li; Y S Gu; X Z Liu
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

10.  Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination.

Authors:  Richard A Moore; Gina Ogilvie; Daniel Fornika; Veronika Moravan; Marc Brisson; Mahsa Amirabbasi-Beik; Anita Kollar; Thomas Burgess; Ray Hsu; Laura Towers; Jane Lo; Jasenka Matisic; Angela Brooks-Wilson
Journal:  Cancer Causes Control       Date:  2009-05-29       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.